SCHEMBL5538835

SCHEMBL5538835

CCOC(=O)CC(=O)N(CCCN1CCCCC1=O)c1cc(Cc2ccc(F)cc2)cnc1C(=O)OCC

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 1/20 0.37
EPHX2 P34913 1/20 0.36
RAB9A P51151 1/20 0.35
EGFR P00533 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP3A4 P08684 1/20 0.34
XIAP P98170 1/20 0.34
BIRC2 Q13490 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538851 0.99 PDE3B (0.38) PDE3BPDE3ASIRT2SIRT1ALDH1A1
SCHEMBL5538668 0.98 PDE3B (0.40) PDE3BPDE3ASIRT2SIRT1ALDH1A1
SCHEMBL5545354 0.94 EPHX2 (0.42) PDE3BPDE3ASIRT2SIRT1ALDH1A1
SCHEMBL5544805 0.85 RAB9A (0.36) PDE3BPDE3AALDH1A1MAPTRAB9A
SCHEMBL5540690 0.84 MAOB (0.35) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL5539039 0.84 ALDH1A1 (0.40) ALDH1A1MAPTCYP3A4CYP2C19HSD17B10
SCHEMBL5541250 0.83 GRM2 (0.35) PDE3BPDE3AALDH1A1SMN1; SMN2CYP2C19
SCHEMBL5541256 0.82 PDE3B (0.34) PDE3BPDE3AALDH1A1EPHX2SMN1; SMN2
SCHEMBL5540997 0.82 PDE3B (0.35) PDE3BPDE3AALDH1A1RAB9ASMN1; SMN2
SCHEMBL5545808 0.82 ALDH1A1 (0.43) PDE3BPDE3ASIRT2SIRT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 PDE3B 3560/4885PDE3A 3339/4885SIRT2 526/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 PDE3B 3316/4885PDE3A 3100/4885SIRT2 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.